綜述 參考文獻(xiàn)

1、1.Global Initiative for Chronic Obstructive Lung Disease (GOLD. 2015.Available at: . 20152.中華醫(yī)學(xué)會呼吸病學(xué)分會慢性阻塞性肺疾病學(xué)組. 慢性阻塞性肺疾病診治指南(2013年修訂版.中華結(jié)核和呼吸雜志,2013,36(4:1-10.3.Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructivepulmonary disease in China: a large, population-bas

2、ed survey. Am J RespirCrit Care Med, 2007, 176(8: 753-760.4.He QY, Zhou X, Xie CM, et al. Impact of chronic obstructive pulmonarydisease on quality of life and economic burden in Chinese urban areas.Zhong Hua Jie He He Hu Xi ZaZhi, 2009,32:253257.5.Lou P, Zhu Y, Chen P, et al. Vulnerability, beliefs

3、, treatments and economicburden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study. BMC Public Health, 2012,12:287.6. 4 World Health Organization. The World Health Report 2008 -primaryHealth Care (Now More Than Ever. Geneva, Switzerland,2008. Available online:

4、http:/www. /whr/2008/en/7.Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonarydisease. Lancet, 2012, 379: 1341-1351.8.Sethi S: Bacteria in exacerbations of chronic obstructive pulmonarydisease: phenomenon or epiphenomenon? Proc Am ThoracSoc, 2004, 1(2:109-114.9.Lindenauer PK,

5、Pekow P, Gao S, et al. Quality of care for patientshospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 2006, 144(12:894903.10.Lopez-Campos JL, Hartl S, Pozo-Rodriguez F,et al. Antibiotic prescriptionfor COPD exacerbations admitted to hospital: European COPD

6、 audit. PLoS One 2015;10(4:e0124374.11.Lin C, Pang Q. Meta-analysis and systematic review ofprocalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary disease. ClinRespir J, 2016 Jun 22.12.Brightling CE. Biomarkers that predict and guide therapy for exacerbationsof chronic

7、 obstructive pulmonary disease. Ann Am ThoracSoc, 2013, 10(Suppl:214219.13.Russwurm S, Oberhoffer M, Zipfel PF, et al. Procalcitoninanovelbiochemical marker for the mediator-directed therapy of sepsis. Mol Med Today, 1999,5(7:286287.14.Gendrel D,Bohuon C.Procalcitonin as a marker of bacterial infect

8、ion.Pediatr Infect Dis,2000,19(8: 679-687.15.Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect ofprocalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet, 2004, 363(9409:600607.16.Stolz

9、 D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment ofexacerbations of COPD: a randomized, controlled trial comparingprocalcitonin-guidance with standard therapy. Chest, 2007, 131(1: 919.17.Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-basedguidelines vs standard guid

10、elines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA, 2009, 302(10:10591066.18.Dandona P,Nix D,Wilsou MF,et al. Procalcitonin increase afterendotoxin injection in normal subjects. J ClinEndocrinolMetab, 1994,79(6:1605-1608.19.Mukhopadhyay S, H

11、oidal JR, Mukherjee TK, et al. Role of TNFalpha inpulmonary pathophysiology. Respir Res,2006, 7:125.20.Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 andtumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Resp

12、irCrit Care Med, 1996,153(2:530534.21.Gessner C, Scheibe R, Wotzel M, et al. Exhaled breath condensatecytokine patterns in chronic obstructive pulmonary disease. Respir Med, 2005, 99(10:12291240.22.Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markersand airway infection during acute

13、exacerbation of chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2001, 163(2:349355.23.Grashoff WF, Sont JK, Sterk PJ, et al. Chronic obstructive pulmonarydisease: therole of bronchiolar mast cells and macrophages. Am JPathol,1997, 151(6:1785-1790.24.O'Shaughnessy TC, Ansari TW,

14、Barnes C, et al. Inflammationin bronchialbiopsies of subjects with chronic bronchitis:inverse relationship of CD8+ T lymphocytes with FEV1. Am JRespirCrit Care Med, 1997, 155(3:852-857.25.Lundblad LK, Thompson-Figueroa J, Leclair T, et al. TNF-alphaOver-expression in LungDisease: a Single Cause Behi

15、nd a Complex Phenotype. Am JRespirCrit Care Med, 2005, 171(12:1363-1370.26.Jiang L, He B, Zhao MW,et al. Association ofgene polymorphisms oftumour necrosis factor-alpha andinterleukin-13 with chronic obstructive pulmonary disease inHan nationality in Beijing. Chin Med J (Engl, 2005, 118(7:541-547.27

16、.Dal Negro RW, Micheletto C, Tognella S, et al. A Two-stage Logistic ModelBased on the Measurement of Pro-Inflammatory Cytokines in Bronchial Secretions for Assessing Bacterial, Viral and Non-infectious Originof COPD Exacerbations. J COPD, 2005, 2(1:7-16.28.Aderka D, Levo Y. Interleukin-6: biologica

17、l characteristics and clinicalimportance. Harefuah, 1990, 118(7:402-404.29.He B, Zhao MW, Wang YZ, et al. The study of inflammatory mediators andpulmonary ventilatory capacity in patients with chronic obstructive pulmonary disease. ZhonghuaJie He He Hu Xi ZaZhi, 2003, 26(1:22-25.Chinese.30.李雯,徐永健,魏華

18、平. 白介素-4和白介素-6在慢性阻塞性肺病肺組織中的表達(dá). 中國組織化學(xué)與細(xì)胞化學(xué)雜志, 2001,10(4:425-42831.Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lowerairway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2006, 173(1:71-78.32.Wedzicha JA, Seemungal TA, MacCallum PK

19、, etal.Acute exacerbations ofchronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. ThrombHaemost, 2000,84(2:210-215.33.Lim SC, Ju JY, Chi SY, et al. Apoptosis of T lymphocytes isolatedfromperipheral blood of patients with acute exacerbation o

20、f chronic obstructive pulmonary disease. Yonsei Med J,2011, 52:581587.34.Karadag F, Karul AB, Cildag O, et al. Biomarkers of systemic inflammationin stable and exacerbation phases of COPD. Lung,2008, 186:403409. 35.Groenewegen KH, Dentener MA, Wouters EFM. Longitudinal follow-up ofsystemic inflammat

21、ion after acute exacerbations of COPD. Respir Med,2007,101: 24092415.36.Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recoveryand recurrence at COPD exacerbation. EurRespir J,2007, 29: 527534. 37.Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical andphysiologic

22、al changes in patients hospitalized for exacerbation of COPD.Chest,2007,131: 3743.38.Chang C, Guo Z, Shen N, et al. Dynamics of inflammation resolution andsymptom recovery during AECOPD treatment. Sci Rep 2014,4: 5516. doi: 10.1038/srep05516 PMID: 24980048. 39. Pinto-Plata VM, Livnat G, Girish M, et

23、 al. Systemic cytokines,clinical and physiological changes in patients hospitalized forexacerbation of COPD. Chest, 2007,131(1:37-43. 40. Chang C, Yao W. Time course of inflammation resolution in patients with frequent exacerbations of chronic obstructive pulmonary disease. Med SciMonit,2014, 20: 31

24、1320. 41. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemicin ammation and decline in lung function in patients with COPD. Chest.2005 ， 128(4:19952004. 42. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by e

25、levations of plasma fibrinogen and serum IL-6 levels. ThrombHaemost ， 2000 ， 84(2:210215. 43. Baggiolini M, Walz A, Kunkel SL, et al. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.JClin Invest, 1989, 84:10451049. 44. Yamamoto C, Yoneda T, Yoshikawa M, et

26、al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest,1997,112:505510. 45. Willemse BW, ten Hacken NH, Rutgers B, Postma DS, Timens W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res. 20

27、05;6:38. 46. Maria Rosedália de Moraes,Adeliane Castro da Costa,Krislainy de Sousa Corrêa, et al. Interleukin-6 and interleukin-8 blood levels poor association with the severity and clinical profile of ex-smokers with COPD.Int J ChronObstruct Pulmon Dis, 2014, 9: 735743. 47. Huang AX, Lu L

28、W, Liu WJ,et al.Plasma Inflammatory Cytokine IL-4, IL-8, IL-10, and TNF- Levels Correlate with Pulmonary Function in Patients with Asthma-Chronic Obstructive Pulmonary Disease (COPD Overlap Syndrome. Med SciMonit, 2016,22:2800-2808. 48. Kim SH, Han SY, Azam T, et al. Interleukin-32: a cytokine and i

29、nducer of TNF alpha. Immunity. 2005, 22(1:131-142. 49. Tanaka G, Kanaji S, Hirano A, et al. Induction and activation of thearyl Hydrocarbon receptor by interleukin- 4 in B cells. Intlmmunol ， 2005 ， 17(6:797-805. 50. Goda C，Kanaji T，Kanaji S，et al. Involvement of IL-32 in activation induced cell dea

30、th in T cells. Intlmmunol，2006，18(2:233-240. 51. Kim SJ, Lee S, Kwak A, et al. Interleukin-32 transgenic mice resist LPS-mediated septic shock. J MicrobiolBiotechnol, 2014, 24 (8: 1133-1142. 52. Hong J, Bae S, Kang Y, et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine, 2010, 49 (2: 171-176. 53. Ca